Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LUCAR-G79 in Relapsed/Refractory Autoimmune Diseases
NCT07049081Phase 1Terminated
- Sponsor
- Legend Biotech Corporation
- Start
- Jul 2025
- Primary completion
- Mar 2026
- Modality
- CAR-T Cells
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of LUCAR-G79 T cells in systemic lupus erythematosus (SLE), systemic sclerosis (SSc), anti-neutrophil cytoplasmic antibody-associated vasculitis (AAV) and 3 more, sponsored by Legend Biotech Corporation. Primary endpoints: Treatment-Emergent Adverse Events at 2 years, Dose-Limiting Toxicity at 2 years and 2 more. Started Jul 2025; status: terminated.
02
Drugs
LUCAR-G79 T cells
03
Conditions
systemic lupus erythematosus (SLE)systemic sclerosis (SSc)anti-neutrophil cytoplasmic antibody-associated vasculitis (AAV)idiopathic inflammatory myopathy (IIM)Takayasu arteritis (TAK)
Beyond the preview
Go deeper on NCT07049081.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07049081.